The decision reverses an administrative judge’s ruling that dismissed the FTC’s initial challenge of Illumina’s $7.1 billion Grail deal.
Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail
){kind=link}
){kind=link}